Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Ypsomed Holding AG's Revenue for the
six
months ended in Mar. 2026 was CHF368.3 Mil. Ypsomed Holding AG's average Accounts Receivable for the
six
months ended in Mar. 2026 was CHF164.5 Mil.
Hence, Ypsomed Holding AG's Receivables Turnover for the
six
months ended in Mar. 2026 was 2.24.
Ypsomed Holding AG (LTS:0QLQ) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Ypsomed Holding AG Receivables Turnover Related Terms
Ypsomed Holding AG Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Ypsomed Holding AG's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QLQ vs ISRG, BDX, MDLN: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Ypsomed Holding AG's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ypsomed Holding AG Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ypsomed Holding AG's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Ypsomed Holding AG's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ypsomed Holding AG (LTS:0QLQ) has a Receivables Turnover of 2.24 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ypsomed Holding AG and its competitors. According to the industry distribution chart, Ypsomed Holding AG ranks #564 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 69.5%.
Is Ypsomed Holding AG's Receivables Turnover too high?
Ypsomed Holding AG's current Receivables Turnover is 2.24. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Ypsomed Holding AG's value of 2.24 is 59.3% below this industry median. Based on the distribution chart, Ypsomed Holding AG ranks #564 out of 812 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Ypsomed Holding AG has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ypsomed Holding AG ranks #564 out of 812 companies for Receivables Turnover. This places Ypsomed Holding AG in the lower half of its industry. The industry median Receivables Turnover is 5.51. Ypsomed Holding AG's value of 2.24 is 59.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ypsomed Holding AG's current Receivables Turnover of 2.24 is 59.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ypsomed Holding AG and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ypsomed Holding AG's current Receivables Turnover is 2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (LTS:0QLQ) is currently considered Fairly Valued. The stock's GF Value™ is CHF396.59, compared to a current price of CHF369.54 — trading 6.8% below its estimated fair value. The current Receivables Turnover is 2.24 and 59.3% below the Medical Devices & Instruments industry median of 5.51. Ypsomed Holding AG's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Ypsomed Holding AG (LTS:0QLQ), the current Receivables Turnover is 2.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ypsomed Holding AG (LTS:0QLQ) Overvalued in 2026?
Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued.
The current stock price of CHF369.54 is trading 6.8% below its estimated GF Value™ of CHF396.59.
GuruFocus considers Ypsomed Holding AG to be Fairly Valued.
Key valuation signals for LTS:0QLQ:
Receivables Turnover: 2.24
GF Value™: CHF396.59 vs. price of CHF369.54 (6.8% below fair value)
Industry Position: 59.3% below the Medical Devices & Instruments median (#564 of 812)
No single metric tells the full story. See the LTS:0QLQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
82GF Score
Get the complete analysis for LTS:0QLQ
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QLQ has been successfully added to your 
